Skip to main content

Xyzal FDA Approval History

FDA Approved: Yes (First approved May 25, 2007)
Brand name: Xyzal
Generic name: levocetirizine dihydrochloride
Company: UCB, Inc. and sanofi-aventis
Treatment for: Allergic Rhinitis, Allergic Urticaria

Xyzal (levocetirizine) is an antihistamine for the relief of symptoms associated with allergic rhinitis and urticaria.

Development timeline for Xyzal

DateArticle
Feb  1, 2017Approval Sanofi's Xyzal Allergy 24HR Approved for Over-the-Counter Use
Aug 25, 2009Approval FDA Approves Xyzal For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria
Feb 19, 2008Approval FDA Approves Xyzal (levocetirizine dihydrochloride) Oral Solutionfor the Relief of Seasonal and Year Round Allergies and ChronicIdiopathic Urticaria
May 29, 2007Approval FDA Approves Xyzal (Levocetirizine Dihydrochloride) Tablets for theRelief of Seasonal and Year Round Allergies, and Chronic Hives
Jul 27, 2006UCB, Inc. Submits New Drug Application to FDA for Xyzal

See also

Xyzal (levocetirizine dihydrochloride) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer